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Background: In this paper we present a systematic literature overview and analysis of the ﬁrst results and
progress made with minimally-invasive surgery using RF energy in the treatment of AF. The minimally-
invasive treatment for atrial ﬁbrillation (AF) tries to combine the success rate of surgical treatment with a
less invasive approach to surgery. It has the additional potential advantage of ganglion plexus (GP) ablation
and left atrial appendage exclusion. Furthermore, additional left atrial ablation lines (ALAL) can be created in
non-paroxysmal AF patients.
Methods: For the search query multiple databases were used. Exclusion and inclusion criteria were applied to
select the publications to be screened. All remaining articles were critically appraised and only relevant and
valid articles were included in our results.
Results: Twenty-three studies were included. In 15 studies GPs around the pulmonary veins were ablated. In
four studies ALAL were performed. Single procedure success rate was 69% (95% CI, range 58%–78%) without
antiarrhythmic drugs (AAD) and 79% (95% CI, range 71%–85%) with AAD at one year follow-up. Mortality was
0.4%, and various complications were reported (3.2% surgical, 3.2% post-surgical, 2.6% cardiac, 2.1% pulmonary,
1.7% other).
Conclusions: Twenty-three studies of minimally-invasive surgery for AF have been reviewed with success rates
between that of the standardmaze procedure and catheter ablation. These ﬁrst combined results showpromise;
however, minimally-invasive surgery is still evolving, for instance by the recent inclusion of electrophysiological
endpoints. Furthermore, the type of ALAL and the additional value of GP ablation have to be elucidated.© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Treatment of AF, worldwide the most common supraventricular
arrhythmia, is a challenge for the cardiologist, despite increasing
pharmalogical and technological options. Some patients experience
no or few complaints during AF while others are adequately managed
with pharmacologic rate or rhythm control. Unfortunately, there is a
group of patients with AF who have debilitating symptoms during AF
that cannot sufﬁciently be treated with AAD. The Cox–Maze procedure
described by Cox et al. was the ﬁrst invasive surgical procedure for thel ﬁbrillation; ALAL, additional
nce interval; GP, ganglionated
ersistent; PVI, pulmonary vein
, The Hague, Netherlands.
gy, Academic Medical Centre,
sterdam, The Netherlands.
t).
nder the Elsevier OA license. treatment of AF [1,2]. It has a success rate of 75%–95% after up to
15 years of follow up. In 1998 Haïssageurre et al. published a landmark
paper in which an endovascular approach was described to target
pulmonary vein triggers [3]. Catheter based interventions have a
lower single procedure success rate of 57% (95% CI, range 50%–64%)
off AAD after a mean follow up of 14 months, but are less invasive
than the Cox–Maze-III procedure, which requires open heart surgery.
Indeed, a single procedure is not always enough to prevent AF recur-
rences and most patients require multiple procedures to achieve a
success rate of 71% (95% CI, 65%–77%) off AAD [4]. In 2005 Wolf et al.
described the ﬁrst results of 21 patients treated with a minimally-
invasive surgical approach to PVI [5]. Theminimally-invasive procedure
tries to combine the success rate of surgical treatment with a less inva-
sive intervention for the patient akin to catheter ablation. Since the
ﬁrst publications, experience with the minimally-invasive procedure
has increased, but the technique has not yet been established as a regular
treatment option of AF. A potential advantage of the epicardial approach
is the possibility of GP ablation, which may modulate the substrate for
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rence and AT in patients requiring more extensive ablation. The risk of
embolic events might be reduced through the possibility of excluding
the LAA during surgery. Multiple energy sources have been investigated,
includingmicrowave [7–9] or high frequency ultrasound [10], but appli-
cation of these energy sources results in a lower success rate than RF
energy. In this paper we present an analysis of the ﬁrst results and
progress made with minimally-invasive surgery, using RF energy only,
in the treatment of AF. Additionally we discuss the recent developments
and the place ofminimally-invasive surgery in the therapeutic options of
AF-treatment.
2. Methods
2.1. Search query
For the search query the following databases were used; Pubmed and Embase on
07/07/2011. The search query is shown in Table 1. We have added the results of
Pison et al. (Pison et al., submitted) to the analysis.
2.2. Search strategy
The exclusion criteria were chosen to make a selection based on title and/or abstract,
hereby selecting the papers needed to screen. Inclusion criteria were applied on the full
text of the selected articles. Exclusion and inclusion criteria are listed in Table 1. Studies
using RF-energy were selected as this method of ablations shows superior results
compared with other energy sources like high intensity focused ultrasound [10] and
microwave ablation [7–9]. Doubles were ﬁltered manually and all remaining articles
were combined. All included full texts were screened on references.
2.3. Statistical analysis
Forest-plots to present an overview of the studies have been made using Meta-
Analyst Beta 3.13 (Tufts Medical Center, Boston, MA) [11]. No individual patient data
were available to perform a meta-analysis; however an overall freedom of AF curve
wasmade to show the results of all studies. A freedom fromAF analysis curve was chosen
to estimate the combined effect of the different studies based on the reported proportions
of success and number of patients. The analysis was performed with the Statistical Pack-
age for the Social Sciences, version 15.0 for Windows XP (SPSS, Chicago, IL, USA).
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
3. Results
A total of 24 studies were found using our search query in Embase
of whom 22 were also found in Pubmed [5,12–31]. Two studies on
≤10 patients were excluded [32,33]. An overview of the remaining
22 studies and the study of Pison et al. is presented in Table 2. All
studies were observational in nature and 18/23 studieswere performed
in a single centre [5,13–18,20–23,26,27,29–31,34]. In total there wereTable 1
Search query.
Database Search query Search results
Pubmed (atrial ﬁbrillation[tiab] OR AF[tiab]) AND (epicardial
ablation[tiab] OR endoscopic[tiab] OR thoracoscopic
[tiab] OR videothoracoscopy[tiab] OR surgical ablation
[tiab] OR minimally invasive[tiab] OR minimal invasive
[tiab] OR mini-maze[tiab] OR VATS[tiab] OR epicardial
pulmonary vein isolation[tiab] OR surgical pulmonary
vein isolation[tiab])
Total: 538
Exclusion: 32
Inclusion: 21
Embase (“atrial ﬁbrillation”:ti,ab OR “AF”:ti,ab) AND (“epicardial
ablation”:ti,ab OR “endoscopic”:ti,ab OR “thoracoscopic”:
ti,ab OR “videothoracoscopy”:ti,ab OR “surgical ablation”:
ti,ab OR “minimal invasive”:ti,abOR “minimally invasive”:
ti,ab OR “mini-maze”:ti,ab OR “VATS”:ti,ab OR “epicardial
pulmonary vein isolation”:ti,ab OR “surgical pulmonary
vein isolation”:ti,ab)
Total: 632
Exclusion: 43
Inclusion: 23
The search was performed on 07-07-2011.
Exclusion criteria: Animal studies, reviews, case reports, concomitant surgery, not atrial
ﬁbrillation, not minimally-invasive surgery, not English, no full-text availability.
Inclusion criteria: Studies with >10 patients, follow-up of >3 months, use of radio
frequent energy, off-pump cardiac surgery.ﬁve studies by the group of Edgerton et al. who report on overlapping
patients [21–25]. Therefore their papers of 2007 and 2008 have been
excluded from analysis in calculations of complications [21,22]. The
paper of Wang et al. [31] describes an open-label randomized trail
where patients received irbesartan after minimally-invasive surgery.
For calculations of the cumulative results only the patients not receiving
irbesartan were selected. There were two studies by the group of
Speziale and Nasso, who performed a monolateral thoracotomy. As
this procedure has different surgical approach, it has been excluded
from the cumulative analysis, but the results of these studies can be
found in Tables 2 and 3.
3.1. Surgery
In all but two studies bilateral thoracotomy or thorascopic approach
to surgery was performed, only the group of Speziale and Nasso used a
monolateral thoracotomy [12,16]. Two studies performed a hybrid
procedure; Krul et al. [30] performed extensive electrophysiological
measurements epicardially while Pison et al. performed simultaneous
transvenous catheter measurements. There were differences in the
execution of the minimally-invasive surgical procedure (Table 2).
RF energy was used in all studies as this was a selection criterion in
including the studies in this paper. GP ablation was performed in
14 of 22 studies in addition to PVI (Table 2). Irrespective of the choice
of GP ablation the ligament of Marshall was divided in all but two
studies [12,16]. ALAL were made in four studies as shown in Table 2
[17,23,30]. The LAA was excluded through suturing or stapling in 20
of 22 studies [5,13–15,17–31,34]. From studies of which procedure
data were available, the mean procedure duration is 208 minutes
(n=12 studies [5,13,14,17–20,26,28,30,31]) and hospital admission is
5 days (n=17 studies [5,13,14,17–20,23–28,30,31,34]).
3.2. Outcome
Deﬁnition of success varied between studies, but unfortunately not
all studies report according to the HRS/EHRA/ECAS expert consensus
statement on catheter and surgical ablation of AF (Tables 2 and 3) [35].
All papers present a total number of patients of 842who underwent
surgery. The reported population comprised of 752 patients. This num-
ber is lower because some patients were lost for follow-up or were still
in the 3 months blanking period following the procedure at the time of
publication.
In these studies a mean of 26% (range 5%–45%, n=15 studies) of
patients had a history of a previous catheter ablation (excluding Castella
et al. [27], where all patients had a previous catheter ablation). Total
follow up varied from 2 to 45 months, with a reported mean ranging
from 5.7–18months. Unfortunately 6 month and/or 12 month follow-
up were not reported in all studies. It was not always possible to assess
the success percentage at these times of follow up. Results in the differ-
ent types of AF and the use of AADwere not speciﬁed in every study and
as such not all studies could be included in the respective pooled
analysis.
Given these restrictions, the overall single procedure success rate
of minimally-invasive surgery without AAD is 64% (95% CI, range
55%–72%, n=7 studies) at a follow-up of 6 months and 69% (95%
CI, range 58%–78%, n=5 studies) at 12 months follow-up.
With AAD the single procedure success rate was 75% (95% CI,
range 70%–80%, n=5 studies) the 6-months of follow up (Fig. 1). At
12-months success rate was comparable at 79% (95% CI, range 71%–
85%, n=7 studies) with AAD (Fig. 1).
In studies with GP ablation the overall success rate is 63% with
AAD (95% CI, range 58%–69%, n=15 studies) while in studies where
the investigators refrained from GP ablation, the success rate was
83% with AAD (95% CI, range 63%–94%, n=6 studies).
In studies with ALAL the overall success rate is 77% with AAD (95%
CI, range 53%–92%, n=4 studies) while in studies where the
Table 2
Minimally-invasive surgery for atrial ﬁbrillation: studies overview.
First author Year No of centres GP ablation ALAL ablation AF endpoints Follow up Rhythm monitoring
Wolf [5] 2005 Single No No Not speciﬁed Ofﬁce visits, medical records, telephone
calls to the patients, records from
cardiology visits
ECG, outpatient telemonitoring
Sagbas [18] 2006 Single No No Not speciﬁed End of the surgical procedure, 3 months
and 6months
ECG, Holter
Edgerton [21] 2007 Single Yes No No episodes of AF longer than 15 seconds
at 6 months
Outpatient visit at 1, 3 and 6 months ECG, Holter, event recorder, pacemaker
Wudel [14] 2007 Single No No Not speciﬁed Outpatient visit at 3, 6, 12 months,
and then until end of study
ECG, Holter
McClelland [34] 2007 Single Yes No Free of AAD (class IC and III) and AF, no
more than 30 seconds of AF after 3 months
Outpatient visit at 1, 2, 3, 6 weeks,
and 3, 6 months, then every 6 months
ECG, Holter, event recorder
Matsutani [19] 2008 Two Yes No Not speciﬁed Not speciﬁed ECG, questionnaires
Edgerton [22] 2008 Single Yes No No episodes of AF longer than 15 seconds
at 6 months
Outpatient visit at 1, 3 and 6 months ECG, Holter, event recorder, pacemaker
Sirak [17] 2008 Single Yes Yesa No episode of AF or AFT lasting 30 s after
blanking period of 3 months
Outpatient visit 3, 6 and 13 months ECG, event recorder
Beyer [28] 2009 Three Yes No Absence of AF or AFT on ECG and Holter Not speciﬁed ECG, Holter
Edgerton [24] 2009 Multi Yes No No episodes of AF and no AAD Outpatient visit at 1, 3 and 6 months ECG, Holter, event recorder, pacemaker
Bagge [29] 2009 Single Yes No No documented symptomatic AF or AT
after 12 months of follow up on ECG,
24 h Holter and spot ECG
Outpatient visit at 3, 6 and 12 months ECG, Holter
Han [20] 2009 Single Yes No No AF /AFT/AT more than 30 s on ECG or
Holter monitoring off AAD
Outpatient visit at 6, 12 months and
12 months thereafter
ECG, Holter, event recorder, pacemaker
Edgerton ELS [23] 2009 Single Yes Yesb No episodes of AF/AFT/AT more than 15 s
during monitoring at 6 months
Outpatient visit at 1, 3, and 6 months ECG, event recorder
Edgerton [25] 2010 Two Yes No No episodes of AF/AFT/AT more than 30 s
on ECG or Holter monitoring
Outpatient visit at 1, 3, 6 and 12months ECG, Holter, event recorder, pacemaker
Speziale [16] 2010 Single No No Absence of AF or other SVT 6 months after
surgery on Holter
Outpatient visit at 3, 6 and 12 months ECG, Holter, echocardiogram
Cui [26] 2010 Single No No No AF or AFT more than 30 s on ECG or
Holter monitoring
Outpatient visit at 1, 3, 6 and 12months ECG, Holter, echo, pacemaker
Castella [27] 2010 Single No No No symptomatic episode of arrhythmia or
SVT lasting more than 30 s in any ECG or
Holter
Outpatient visit at 1, 4, 6 and 12months ECG, Holter, echo
Stamou [15] 2010 Single Yes No Not speciﬁed Not speciﬁed Not speciﬁed
Yilmaz [13] 2010 Single Yes No No episode of AF more than 30 s after
blanking period of 3 months
Outpatient visit at 1 and 3 weeks and
3, 6, 12 months
ECG, Holter, refering physician
Krul [30] 2011 Single Yes Yesc No AF/AFT/AT more than 30 s on ECG or
Holter monitoring of AAD
Outpatient visit at 3, 6, 12, 15, 18, 24
months
ECG, Holter, MRI
Pison 2011 Single Yes Yesd No AF/AFT/AT more than 30 s on ECG or
Holter monitoring of AAD
Outpatient visit at 3, 6 and 12 months ECG, Holter
Wang [31] 2011 Single Yes No No AF/AFT more than 30 s on ECG or
Holter monitoring
Outpatient visit at 1, 3, 6, and 12months
for clinical interview,
ECG, Holter, echocardiogram
Nasso [12] 2011 Single No No One year clincical results of rate of
recurrence of AF, freedom from,
antiarrhytmic medications
Outpatient visit at 3, 6 and 12 months ECG, Holter, echocardiogram
AAD: antiarrhythmic drugs, AF: atrial ﬁbrillation, AFT: atrial ﬂutter, ALAL: additional left atrial lesions, AT: atrial tachycardia, GP: ganglionic plexus, ELS: extended lesion set, LAA: left atrial appendage, SVT: supraventricular tachycardia.
a Left atrial appendage line and mitral line.
b Roof line, trigone line and left atrial appendage line.
c Roof line, inferior line and trigone line.
d Roof line, inferior line and optional left isthmus line and right atrial lines.
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Table 3
Minimally-invasive surgery for atrial ﬁbrillation: patient number and results overview of studies.
Overall Paroxysmal AF Persistent AF LSP AF
First author Year Operated
patientsa
FU
(months)
Total % Total % Total % Total %
AAD No AAD AAD No AAD AAD No AAD AAD No AAD
Wolf [5] 2005 29 5.7 23 91 65 – – – – – – – – –
Sagbas [18] 2006 26 6 26 – 81 – 100 100 – 72 72 – – –
Edgerton [21] 2007 83 6 57 74 63 39 82 74 18 56 39 – – –
Wudel [14] 2007 23 18 22 – 91 – – – – – – – – –
McClelland [34] 2007 20 12 20 – 75 – 91 91 – 80 80 4 25 25
Matsutani [19] 2008 20 16,6 20 90 85 – – – – – – – – –
Edgerton [22] 2008 74 6 66 74 58 43 84 70 23 57 35 – – –
Sirak [17] 2008 32 6 24 – 88 – – – – – – – – –
Beyer [28] 2009 100 13.6 100 87 63 39 93 – 29 96 – – 71 –
Edgerton [24] 2009 114 6 114 71 57 60 87 72 32 56 47 22 50 32
Bagge [29] 2009 43 12 33 76 52 24 79 – 2 100 – – 57 –
Han [20] 2009 45 12 43 – 65 – 70 70 – 58 58 – – –
Edgerton ELS [23] 2009 30 6 30 80 47 – – – 10 90 70 20 75 35
Edgerton [25] 2010 52 12 52 81 63 52 81 63 – – – – – –
Speziale [16] 2010 54 6 46 87 – 19 95 – 27 81 – – – –
Cui [26] 2010 81 12 49 80 – – 80 – – 75 – – 67 –
Castella [27] 2010 38 12 26 62 – 11 82 – 10 60 – – 20 –
Stamou [15] 2010 20 12 12 75 – 7 100 – 5 40 – – – –
Yilmaz [13] 2010 30 11.6 30 77 50 19 84 – 8 75 – – 33 –
Krul [30] 2011 31 12 22 91 86 12 100 92 9 78 78 1 100 100
Pison 2011 26 12 24 92 83 14 93 79 11 90 90 – – –
Wang [31] 2011 83 24 81 – 80 – – – – – – 81 – 80
Nasso [12] 2011 104 12 104 89 53 – 96 – – 80 – – – –
AAD: antiarrhythmic drugs, AF: atrial ﬁbrillation, ELS: extended lesion set, FU: follow-up, LSP AF: long standing persistent atrial ﬁbrillation.
a Total number of patients who underwent the procedure is higher than overall reported patients because some patients did not complete the procedure or were still in the
3 months blanking period during publication.
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(95% CI, range 60%–70%, n=16 studies).
Speciﬁed to the different type of AF, success in paroxysmal AF was
71% (95% CI, range 65%–77%, n=5 studies), persistent AF 51% (95% CI,
range 36%–65%, n=5 studies) (Fig. 2) and for LSP AF 33% (95% CI,
range 21%–49%, n=2 studies) at 6 months (Fig. 2). Success at
12 months with paroxysmal AF was 75% (95% CI, range 66%–82%,
n=8 studies) and 67% (95% CI, range 52%–79%, n=7 studies) in per-
sistent AF (Fig. 2) and 43% (95% CI, range 21%–68%, n=4 studies) in
LSP AF.
3.3. Complications
Three casualties have been reported during or within 30 days after
the procedure. One occurred during the procedure as a consequence of
tearing of the LAA. For one death, the day after the procedure, the
cause of death was undetermined and lastly, one late death resulted
from cerebral infarction 30 days after the procedure. While mortality
is low, surgical and post-procedural complications are relatively more
frequently encountered. In 1.7% (14/842) of the procedures a sternotomy
was required to control bleeding. Predominantly surgical complications
of 3.2%, post-surgical complications of 3.2% and cardiac complications
of 2.6% were described in the selected papers. A full list of morbidity
related to the minimally-invasive procedure is listed in Table 4.
4. Discussion
4.1. Minimally-invasive surgery
This systematic review comprises the ﬁrst cumulative results of
minimally-invasive surgery. These studies report an overall single proce-
dure success rate of 69% without AAD and 79% with AAD at one year. In-
terestingly the results at 6 months are somewhat lower (64% without
AAD and 75% with AAD) (Fig. 3). There can be two explanations for this
ﬁnding; ﬁrstly studies reporting results at 6 months follow-up represent
the very ﬁrst published reports of minimally-invasive surgery as can beappreciated from Table 3. Secondly not all people are weaned of their
AAD at 6 months after the procedure. Most studies in this review use
similar methods and have a mixed AF population (paroxysmal, per-
sistent and LSP). Only one paper describes the results in a group of
paroxysmal AF [25] and three papers in only persistent and LSP AF
[17,23,31]. Minimally-invasive surgery is most effective in paroxys-
mal AF, but even in persistent AF and LSP AFmore than half of the pa-
tients beneﬁt from minimally-invasive surgery (Fig. 2). A recurrence
of AF over time appears to be present, similar to the time course of re-
currences after catheter ablation [36]. Invasive ablation of AF is helpful
to the majority of selected patients, but the disease progresses and
causes recurrences in part of the patients. Comparison between cathe-
ter based PVI and minimally-invasive surgery is not possible; ﬁrst,
these are the ﬁrst cumulative results of minimally-invasive surgery
and secondly, no randomized control trial has been published com-
paring these two treatment modalities. Yet, while minimally-
invasive PVI appear at least equally successful, catheter based PVI
and minimally-invasive surgery have the same limitation. Both treat-
ment strategies only aim to eliminate a trigger of AF, namely ectopic
triggers from the pulmonary veins. Recently substrate modiﬁcation
with the use of additional left atrial lines has been proposed to
increase success rates in non-paroxysmal AF.
A substantial part of the population reported in the papers had
one or more previous catheter ablation (mean 26%). This might inﬂu-
ence the results with minimally-invasive surgery; these patients
might have incomplete lesions leading to AT, which are difﬁcult to
treat because these lesions are not easily identiﬁable. However the
pre-existent substrate modiﬁcation and PVI ablation might also in-
crease the success rate of minimally-invasive surgery. Interestingly,
Castella et al. [27] have, compared to other investigators, a moderate
procedural success rate (62% with AAD), but they report results of
patients with an earlier failed catheter-PVI only. These patients
might have had different substrates in which PVI does not eliminate
the pathophysiologic mechanism completely.
Speziale et al. and Nasso et al. [12,16] used a monolateral approach
and only performed PVI, without electrophysiological measurements.
Fig. 1. Thisﬁgure shows four forest plots representing the proportion of the patients in sinus rhythm at 6 months and 12 months. The top left plot shows the results at 6 monthswithout AAD (n=7 studies) and the top right at 6 monthswith AAD (n=6
studies). The bottom left plot shows the results at 12 months without AAD (n=6 studies) and the bottom right with AAD (n=7 studies). Note that the 6 months results are mostly results from studies of Edgerton et al. AAD: antiarrhythmic drugs.
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low risk of procedure related-morbidity. Currently there is no
conﬁrmatory experience with this technique. Two studies perform
periprocedural electrophysiological conﬁrmation of conduction
block of PVI and ALAL. Krul et al. [30] use epicardial conﬁrmation
of conduction block while Pison et al. use a endovascular approach.
These studies demonstrate that electrophysiological measure-
ments are feasible during minimally-invasive surgery and that
this hybrid approach might increase the success rate of
minimally-invasive surgery [37].4.2. Role of GP ablation
There is ample evidence from animal studies that neurohumoral
inﬂuence on the PVs plays an important role in the initiation of AF
[6]. Although the precise role of GPs has not yet been established,
the minimally-invasive approach offers access to the epicardial fat
pads where the GPs reside and allows their ablation. Additional
GP ablation can be performed to modify the local neurohumoral
triggers of the atria and it has been hypothesized that this might
decrease recurrence of AF. During epicardial surgery localization
both visually and with high frequency stimulation and subsequent
ablation of the GPs is possible. The absence of a vagal response to
high frequency stimulation after ablation is generally considered
proof of destruction of the GP. GP ablation has been added as a rou-
tine part of the minimally-invasive surgery protocol for AF by some
investigators. However its value in the epicardial treatment of AF
has not been established. There is evidence that endocardial ablation
of GPsmight increase success rate of catheter PVI. A vagal response dur-
ing a catheter PVI procedure is associatedwith a lower recurrence of AF
[38]. In the studies reviewed here, there is a difference between GP ab-
lation (63%) and no GP ablation (83%) in the addition to PVI. This might
indicate that GP ablation is not an essential part in the minimally-
invasive surgery of AF to prevent recurrence of AF. Clearly, follow-up
was short and at the present these data do not allow to draw anymean-
ingful clinical conclusions, and this difference merely underscores the
need for further randomized studies.4.3. Role of left atrial lesions
Four studies have been published that report the creation of an
additional lesion set on the left atrium [17,23,30]. The types of le-
sions are not uniform in these studies but compartmentalization
of the posterior left atrium, to prevent re-entry around the PVs, is
the hallmark of these lesions. These lesions purposefully increase
the success rate in patients with persistent and LSP AF. From re-
sults with catheter ablation therapy it is suggested that only PVI
in these patient may not be sufﬁcient to prevent recurrence of AF
[39]. The application of RF energy and subsequent visualization of
the lines is possible in minimally-invasive surgery. In our view,
additional electrophysiological testing is required to assess com-
plete block over these lines [40]. It has been demonstrated in
two studies that a large proportion of patients undergoing
minimally-invasive surgery might suffer from atrial tachycardias
[41,42]. Therefore all effort should be taken to produce a lesion
set that actually demonstrates conduction block. Although longer
follow-up is needed, a comprehensive set of left atrial lesions might
increase freedom of AF in patients with persistent or LSP AF. A repro-
ducible set of lesions with peri-operative proof of block can therefore
be a valuable addition to the minimally-invasive procedure. Thus the
types of left atrial lesions that are most effective, are easy reproduc-
ible, and can be thoroughly tested electrophysiologically, should be
investigated and their value in the different types of AF should be
assessed.4.4. Mortality and morbidity
Due to the epicardial approach to PVI minimally-invasive surgery
incurs other risk in comparison with catheter PVI. There is for exam-
ple a risk of conversion to on-pump cardiac surgery due to thoraco-
scopic surgery on the beating heart. However there is no radiation
exposure during the procedure and therefore there are no radiation
related complications. Mortality is limited, especially compared to
other cardiac operations, and appears to be similar with catheter
PVI (incidence minimally-invasive 0.4% vs. catheter ablation 0.7%)
[39]. Surgical and post-procedural complications are frequently en-
countered (Table 4). As can be appreciated from this table the risks
of minimally-invasive surgery are mainly peri-procedural problems
followed by cardiac and pulmonary complications. These complica-
tion rates can be explained through the procedural difﬁculty and
the learning curve of the surgery. Even though most complications
are transient, the risk of pacemaker implantation of 1.4% is substan-
tial. Furthermore there is still a risk of stroke or TIA (0.5%) during or
shortly after minimally-invasive surgery. This risk of occurrence is
not abolished through epicardial ablation, but it is smaller than in
catheter based PVI [39]. The anti-coagulation policy before and
after surgery (when the LAA is excluded) is difﬁcult; the balance be-
tween prevention of embolic events versus prevention of bleeding
complications is precarious. There is little evidence of how to manage
anti-coagulation after the treatment of AF and guidelines currently
suggest maintaining anti-coagulation based on the CHA2DS2VASc
score [39].
4.5. Future developments
The position of minimally-invasive surgery in the treatment of AF
treatment has yet to be established. The results presented in this
paper show the ﬁrst results of minimally-invasive surgery. As such
the potential of minimally-invasive surgery is still to be realized.
Outcomes may beneﬁt from standardization of the technique, results
of longer follow-up and an improved patients selection. Furthermore
recent incorporation of electrophysiological measurements by some
groups might increase the success rates the procedure. At the moment
there are two ongoing studies comparing minimally-invasive surgery
with catheter based PVI (SCALAF-trail and the FAST-trail). In these
studies the two treatment modalities are compared with each other,
but a complementary role of these interventions might be envisioned.
Patient preference can be the decisive factor in choosing catheter
ablation or minimally-invasive surgery when comparing both the
risks and the beneﬁts of the two different approaches.
4.6. Limitations
This systematic review did not have access to all individual
patient data and therefore our results and conclusions are based
on published data. Furthermore not all results are reported accord-
ing to the HRS/EHRA/ECAS expert consensus statement on catheter
and surgical ablation of atrial ﬁbrillation [35] which makes a com-
parison of the different studies difﬁcult. Due to the increasing
experience and knowledge with minimally-invasive surgery, the
technique has evolved signiﬁcantly after the ﬁrst publication.
Results of the ﬁrst studies might not be fully comparable to those
published later. Furthermore, this paper is an overview of
minimally-invasive surgery based on published reports and therefore
might be subject to publication bias and might not reﬂect current prac-
tice in individual centres.
5. Conclusions
Minimally-invasive surgery is a new invasive procedure for the
non-pharmaceutical treatment of AF. The ﬁrst studies describe a
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Fig. 3. Overall freedom from atrial ﬁbrillation curve for minimally-invasive surgery. This ﬁgure shows the overall freedom of AF curve for minimally-invasive surgery using the
reported proportions in the published papers at 6 months and 12 months. The blue line represents the overall results with AAD. The blue dotted line is the conﬁdence interval
of the overall results. Blue circles ( ) represent the different studies and their outcome. Red lines and diamonds ( ) represent results without AAD. AAD: antiarrhythmic drugs,
AF: atrial ﬁbrillation.
Fig. 2. This ﬁgure shows four forest plots representing the proportion of the patients in sinus
at the top show the results at 6 months of paroxysmal AF (n=6 studies) and persistent AF (
studies) and persistent AF (n=8 studies) Of the studies marked with an asterisk (*) only r
Table 4
Minimally-invasive surgery for atrial ﬁbrillation: morbidity.
Morbidity N=842
Surgical complications 27 3.20%
Conversions 14 1.70%
Conversions requiring heart-lung machine 4 0.50%
Bleeding 12 1.40%
LA Bleeding 5 0.60%
PV bleeding 4 0.50%
LAA bleeding 3 0.40%
Other complications 1 0.10%
Post-surgical complications 27 3.20%
Hematothorax 12 1.40%
Nerve injury 10 1.20%
Wound problems 4 0.50%
Ribfracture 1 0.10%
Cardiac complications 22 2.60%
Pacemaker implantation 12 1.40%
Pericarditis 5 0.60%
Ventricular arrhythmias 3 0.40%
Cardiac effusion 2 0.20%
Pulmonary complications 18 2.10%
Ventilation support 9 1.10%
Pneumothorax 5 0.60%
Pulmonary embolism 2 0.20%
Pleural effusion 2 0.20%
Other complications 14 1.70%
Infection 6 0.70%
Stroke/TIA 4 0.50%
Renal insufﬁciency 4 0.50%
Minor complications 3 0.40%
Phlebitis 1 0.10%
Coagluation problems 1 0.10%
Delirium 1 0.10%
LA: left atrium, LAA: left atrial appendage, PV: pulmonary vein, TIA: transient ischemic attack.
139S.P.J. Krul et al. / International Journal of Cardiology 166 (2013) 132–140single procedure success rate of 69% without AAD and 79% with AAD
at one year follow-up. These results show a promising role for
minimally-invasive surgery, although these results are likely to in-
crease as the procedure progresses. Similar to catheter ablation it
has a higher success rate in paroxysmal AF. Electrophysiological mea-
surements and conﬁrmation of the ablation lines might be an impor-
tant factor to increase the success of this procedure. Additional
research in the creation and type of left atrium lines in patients
with persistent and LSP AF should determine a reproducible and ef-
fective left atrial lesion set to prevent recurrences in these types AF.
Furthermore, the additional value of GP ablation is to be elucidated
to asses its role in minimally-invasive surgery.Funding
Netherlands Heart Foundation, 2009T021.Conﬂicts of interest
J.R. de Groot, supported by a personal grant from the Netherlands
Heart Foundation, 2009T021.Acknowledgement
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal
of Cardiology.rhythm at 6 months and 12 months speciﬁed to the different types of AF. The forest plot
n=6 studies).The bottom plots show the results at 12 months of paroxysmal AF (n=9
esults with the use of antiarrhythmic drugs are available. AF; atrial ﬁbrillation.
140 S.P.J. Krul et al. / International Journal of Cardiology 166 (2013) 132–140References
[1] Cox JL, Jaquiss RD, Schuessler RB, et al. Modiﬁcation of the maze procedure for
atrial ﬂutter and atrial ﬁbrillation. II. Surgical technique of the maze III procedure.
J Thorac Cardiovasc Surg 1995;110:485–95.
[2] Cox JL, Boineau JP, Schuessler RB, et al. Modiﬁcation of the maze procedure for
atrial ﬂutter and atrial ﬁbrillation. I. Rationale and surgical results. J Thorac Cardiovasc
Surg 1995;110:473–84.
[3] Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial ﬁbrillation
by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:
659–66.
[4] Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial ﬁbrillation with anti-
arrhythmic drugs or radiofrequency ablation: two systematic literature reviews
and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349–61.
[5] Wolf RK, Schneeberger EW, Osterday R, et al. Video-assisted bilateral pulmonary
vein isolation and left atrial appendage exclusion for atrial ﬁbrillation. J Thorac
Cardiovasc Surg 2005;130:797–802.
[6] Scherlag BJ, Yamanashi W, Patel U, et al. Autonomically induced conversion of
pulmonary vein focal ﬁring into atrial ﬁbrillation. J Am Coll Cardiol 2005;45:
1878–86.
[7] Pruitt JC, Lazzara RR, Ebra G. Minimally invasive surgical ablation of atrial ﬁbrilla-
tion: the thoracoscopic box lesion approach. J Interv Card Electrophysiol 2007;20:
83–7.
[8] Pruitt JC, Lazzara RR, Dworkin GH, et al. Totally endoscopic ablation of lone atrial
ﬁbrillation: initial clinical experience. Ann Thorac Surg 2006;81:1325–30.
[9] Koistinen J, Valtonen M, Savola J, et al. Thoracoscopic microwave ablation of atrial
ﬁbrillation. Interact Cardiovasc Thorac Surg 2007;6:695–8.
[10] Klinkenberg TJ, AhmedS, TenHA, et al. Feasibility and outcomeof epicardial pulmonary
vein isolation for lone atrial ﬁbrillation using minimal invasive surgery and high
intensity focused ultrasound. Europace 2009;11:1624–31.
[11] Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of
binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80.
[12] Nasso G, Bonifazi R, Del PA, et al. Long-term results of ablation for isolated atrial
ﬁbrillation through a rightminithoracotomy: Toward a rational revision of treatment
protocols. J Thorac Cardiovasc Surg 2011;142:e41–6.
[13] Yilmaz A, Geuzebroek GS, Van Putte BP, et al. Completely thoracoscopic pulmonary
vein isolation with ganglionic plexus ablation and left atrial appendage amputa-
tion for treatment of atrial ﬁbrillation. Eur J Cardiothorac Surg 2010;38:356–60.
[14] Wudel JH, Chaudhuri P, Hiller JJ. Video-assisted epicardial ablation and left atrial
appendage exclusion for atrial ﬁbrillation: extended follow-up. Ann Thorac Surg
2008;85:34–8.
[15] Stamou SC, Khabbaz KR, Mahmood F, et al. A multidisciplinary approach to the
minimally invasive pulmonary vein isolation for treatment of atrial ﬁbrillation.
Ann Thorac Surg 2010;89:648–50.
[16] Speziale G, Bonifazi R, Nasso G, et al. Minimally invasive radiofrequency ablation
of lone atrial ﬁbrillation by monolateral right minithoracotomy: operative and
early follow-up results. Ann Thorac Surg 2010;90:161–7.
[17] Sirak J, Jones D, Sun B, et al. Toward a deﬁnitive, totally thoracoscopic procedure
for atrial ﬁbrillation. Ann Thorac Surg 2008;86:1960–4.
[18] Sagbas E, Akpinar B, Sanisoglu I, et al. Video-assisted bilateral epicardial pulmonary
vein isolation for the treatment of lone atrial ﬁbrillation. Ann Thorac Surg 2007;83:
1724–30.
[19] Matsutan N, Takase B, Ozeki Y, et al. Therapeutic strategy for atrial ﬁbrillation by
minimally invasive surgery using athoracoscopic mini maze procedure. Ther Res
2009;30:1129–32.
[20] Han FT, Kasirajan V, Kowalski M, et al. Results of a minimally invasive surgical
pulmonary vein isolation and ganglionic plexi ablation for atrial ﬁbrillation:
single-center experience with 12-month follow-up. Circ Arrhythm Electrophysiol
2009;2:370–7.
[21] Edgerton JR, JackmanWM, Mack MJ. Minimally invasive pulmonary vein isolation
and partial autonomic denervation for surgical treatment of atrial ﬁbrillation.
J Interv Card Electrophysiol 2007;20:89–93.
[22] Edgerton JR, Edgerton ZJ,Weaver T, et al.Minimally invasive pulmonary vein isolation
and partial autonomic denervation for surgical treatment of atrial ﬁbrillation. Ann
Thorac Surg 2008;86:35–8.[23] Edgerton JR, Jackman WM, Mahoney C, et al. Totally thorascopic surgical ablation
of persistent AF and long-standing persistent atrial ﬁbrillation using the “Dallas”
lesion set. Hear Rhythm 2009;6:S64–70.
[24] Edgerton JR, McClelland JH, Duke D, et al. Minimally invasive surgical ablation
of atrial ﬁbrillation: six-month results. J Thorac Cardiovasc Surg 2009;138:
109–13.
[25] Edgerton JR, BrinkmanWT,Weaver T, et al. Pulmonary vein isolation and autonomic
denervation for the management of paroxysmal atrial ﬁbrillation by a minimally
invasive surgical approach. J Thorac Cardiovasc Surg 2010;140:823–8.
[26] Cui YQ, Li Y, Gao F, et al. Video-assisted minimally invasive surgery for lone atrial
ﬁbrillation: a clinical report of 81 cases. J Thorac Cardiovasc Surg 2010;139:
326–32.
[27] Castella M, Pereda D, Mestres CA, et al. Thoracoscopic pulmonary vein isolation in
patients with atrial ﬁbrillation and failed percutaneous ablation. J Thorac Cardiovasc
Surg 2010;140:633–8.
[28] Beyer E, Lee R, Lam BK. Point: minimally invasive bipolar radiofrequency ablation
of lone atrial ﬁbrillation: early multicenter results. J Thorac Cardiovasc Surg
2009;137:521–6.
[29] Bagge L, Blomstrom P, Nilsson L, et al. Epicardial off-pump pulmonary vein isolation
and vagal denervation improve long-term outcome and quality of life in patients
with atrial ﬁbrillation. J Thorac Cardiovasc Surg 2009;137:1265–71.
[30] Krul SP, Driessen AH, Van Boven WJ, et al. Thoracoscopic Video-Assisted Pulmonary
VeinAntrum Isolation, Ganglionated Plexus Ablation and Periprocedural Conﬁrmation
of Ablation Lesions. First Results of a Hybrid Surgical-Electrophysiological Approach
for Atrial Fibrillation. Circ Arrhythm Electrophysiol 2011;4:262–70.
[31] Wang JG, Li Y, Shi JH, et al. Treatment of long-lasting persistent atrial ﬁbrillation
using minimally invasive surgery combined with irbesartan. Ann Thorac Surg
2011;91:1183–9.
[32] Colafranceschi AS, Monteiro AJ, Botelho ES, et al. Videothoracoscopy for isolated
atrial ﬁbrillation ablation through bipolar radiofrequency. Arq Bras Cardiol
2009;93:334–5.
[33] Li H, Li Y, Sun L, et al. Minimally invasive surgical pulmonary vein isolation alone
for persistent atrial ﬁbrillation: preliminary results of epicardial atrial electrogram
analysis. Ann Thorac Surg 2008;86:1219–25.
[34] McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new ap-
proach to treat atrial ﬁbrillation. J Cardiovasc Electrophysiol 2007;18:1289–95.
[35] Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement
on catheter and surgical ablation of atrial ﬁbrillation: recommendations for
personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society
(HRS) Task Force on catheter and surgical ablation of atrial ﬁbrillation. Hear Rhythm
2007;4:816–61.
[36] Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial ﬁbrillation
are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011;57:160–6.
[37] Gersak B, Kiser AC, Bartus K, et al. Importance of evaluating conduction block in
radiofrequency ablation for atrial ﬁbrillation. Eur J Cardiothorac Surg 2012
Jan;41(1):113–8.
[38] Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances
long-term beneﬁt after circumferential ablation for paroxysmal atrial ﬁbrillation.
Circulation 2004;109:327–34.
[39] CammAJ, Kirchhof P, Lip GY, et al. Guidelines for themanagement of atrial ﬁbrillation:
the Task Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC). Europace 2010;12:1360–420.
[40] de Groot JR, Driessen AH, Van Boven WJ, et al. Epicardial conﬁrmation of conduc-
tion block during thoracoscopic surgery for atrial ﬁbrillation - a hybrid surgical-
electrophysiological approach. Minim Invasive Ther Allied Technol 2012
Jul;21(4):293–301.
[41] ZengY, Cui Y, Li Y, et al. Recurrent atrial arrhythmia afterminimally invasive pulmonary
vein isolation for atrial ﬁbrillation. Ann Thorac Surg 2010;90:510–5.
[42] Kron J, Kasirajan V, Wood MA, et al. Management of recurrent atrial arrhythmias
after minimally invasive surgical pulmonary vein isolation and ganglionic plexi
ablation for atrial ﬁbrillation. Hear Rhythm 2010;7:445–51.
